Table 1.

miRNAs as potential biomarkers of resistance to treatments in breast cancer.

Overexpressed miRNA	Predicted Targets	Pathway Involved	Reference
Paclitaxel
miR-Lin28	Let7a	miRNAs processing	[20]
miR-125b	Bak1	Apoptosis	[21]
miR-520h	DAPK2	PI3K/Akt signaling	[22]
miR18a		mTOR signaling	[25]
Docetaxel
miR-129-3p	CP110	G2/M progression and apoptosis	[31]
miR-141	EIF4E	Apoptosis	[30]
miR-3646	GSK-3β	β-catenin signaling pathway	[32]
miR-452	APC4		[33]
miR-663	HSPG2		[34]
miR-34a	BCL-2 and CCND1	Apoptosis	[35]
miR-222 and miR-29a	PTEN	Apoptosis	[39]
Letrozol + anastrozole
miR-125b and miR-205		Akt/mTOR pathway	[53]
Fulvestrant
miR-221 and miR-222	AXIN2, SFRP2, CHD8 and NLK	p53, TGF-β, MAPK, Notch, ErbB and Jak-STAT	[56]
miR-21	PTEN	PI3K-Akt-mTOR pathway	[57]
Tamoxifen
miR-10b	HDAC4	Epithelial-mesenchymal transition	[63]
miR-210	RAD52	Invasion, proliferation and migration	[70]
mirR-155	SOC6	STAT3 signaling pathway	[62]
Trastuzumab
miR-21	PTEN	PI3K-Akt-mTOR/epithelial-to-mesenchymal transition and inflammatory signals	[67]
miR-150-5p and miR-4734			[68]
miR-210	RAD52	Cell survival	[69]
Doxorrubicin miR-141 miR-200c miR-31		MAPK signaling pathway, regulation of the actin cytoskeleton, cytokine-cytokine receptor interaction	[90]
miR-155p miR-21-3p miR-181a-5p miR-181b-5p miR-183-5p		PTEN/Akt, MAPK, MDR1, RhoA, FOXO3 and PDCD4 pathway	[91]
miR-125b miR-141		cell cycle control and apoptotic pathways	[93]
miR-155 miR-493 miR-30e miR-27a			[95]
miR-181a	Bax		[94]
Epirubicin miR-19a miR-205	PTEN		[96]
Adriamycin miR-222	PTEN	PTEN, Akt/FOXP1 pathway	[97]
Cisplatin miR-146a miR-10a miR-221/222 miR-345 miR200b and miR-200c	MRP1	EMT efflux of drugs	[99]
miR-221		BIM-Bax/Bak axis	[100]
miR-944	BNIP3	cell proliferation, migration and invasion	[101]
Gemcitabine miR-21	PTEN	EMT	[113]
Vinorelbine miR-138-5p, miR-182-5p, miR-18a-5p, miR-193b-3p, miR-199a-5p, miR-210-3p, miR-21-5p, miR-378a-3p, miR-4262, miR-4725-5p and miR-92b-3p		MAPK, mTOR, Wnt, and TGF-β	[110]